Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
暂无分享,去创建一个
[1] J. S. Rao,et al. CpG island promoter methylation and silencing of 14-3-3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2 , 2006, Oncogene.
[2] C. Gondi,et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.
[3] C. Gondi,et al. Proteases and Glioma Angiogenesis , 2005, Brain pathology.
[4] Wei Zhao,et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. , 2005, Cancer research.
[5] R. Dahiya,et al. Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer , 2005, Clinical Cancer Research.
[6] Carmen Jerónimo,et al. P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation , 2005, Clinical Cancer Research.
[7] Joachim Diebold,et al. Functional epigenomics identifies genes frequently silenced in prostate cancer. , 2005, Cancer research.
[8] M. Szyf. DNA Methylation and Demethylation as Targets for Anticancer Therapy , 2005, Biochemistry (Moscow).
[9] Kazuhiko Aoyagi,et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. , 2005, Cancer research.
[10] R. Dahiya,et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Shailesh Singh,et al. Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion , 2004, Clinical Cancer Research.
[12] D. McNeel,et al. Newer therapies in advanced prostate cancer. , 2004, Clinical prostate cancer.
[13] Achim Krüger,et al. Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents*[boxs] , 2004, Journal of Biological Chemistry.
[14] M. Szyf,et al. Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis* , 2004, Journal of Biological Chemistry.
[15] G. De Petro,et al. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. , 2004, Molecular cancer therapeutics.
[16] S. Rabbani,et al. Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma , 2004, Clinical Cancer Research.
[17] Robert A Sikes,et al. Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer , 2004, Reproductive biology and endocrinology : RB&E.
[18] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[19] C. Gondi,et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis , 2003, Oncogene.
[20] J. S. Rao,et al. Molecular mechanisms of glioma invasiveness: the role of proteases , 2003, Nature Reviews Cancer.
[21] M. Szyf,et al. The Methyl Donor S-Adenosylmethionine Inhibits Active Demethylation of DNA , 2003, Journal of Biological Chemistry.
[22] S. Rabbani,et al. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Aguirre-Ghiso,et al. ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .
[25] D. Dinh,et al. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. , 2003, International journal of oncology.
[26] Alicia Samuels,et al. Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.
[27] J. Aguirre-Ghiso,et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.
[28] P. Carmeliet,et al. uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.
[29] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.
[30] C. Legrand,et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. , 2001, Experimental cell research.
[31] S. Mohanam,et al. Regulation of the uPA gene in various grades of human glioma cells. , 2001, International journal of oncology.
[32] C. Rinker-Schaeffer,et al. Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.
[33] P. Russell,et al. Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.
[34] A. V. von Eschenbach,et al. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. , 2000, International journal of radiation oncology, biology, physics.
[35] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[36] J. Foekens,et al. Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[37] H. Miyake,et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.
[38] J. Herman,et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.
[39] R. Sadasivan,et al. Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.
[40] E. Hedley‐Whyte,et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.
[41] P. Dettmar,et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.
[42] J. Bruner,et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. , 1994, Cancer research.
[43] F. Blasi,et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.
[44] Michael J. Wilson,et al. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior , 1991, The Prostate.
[45] A. Mazar,et al. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. , 1991, Cancer communications.
[46] I. Fidler,et al. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.
[47] G. Satta,et al. Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio. , 1989, Carcinogenesis.
[48] H. Keer,et al. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.
[49] B. Binder,et al. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. , 1988, The Journal of urology.
[50] K. Danø,et al. immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma , 1984, The Journal of cell biology.